Opsens Receives dPR Clearance from the FDA Product approval will bolster U.S. commercial efforts Quebec City, Quebec, December 19, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its diastolic pressure algorithm (“dPR”). Coronary physiology has been in constant evolution with…
OPSENS RECEIVES dPR CLEARANCE FROM FDA
19 December 2019VISIT OPSENS AT SCAI FALL FELLOWS 2019
2 December 2019Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at the SCAI Fall Fellows 2019 Annual Meeting by attending Opsens’ complimentary educational symposium. The OptoWire features a large nitinol core with excellent torque response and deliverability. With the OptoWire you can diagnose and treat your patients with confidence. Opsens second…